Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/CU-2010_and_CU-2020> ?p ?o }
Showing triples 1 to 26 of
26
with 100 triples per page.
- CU-2010_and_CU-2020 abstract "CU-2010 and CU-2020 are new synthetic compounds that act as serine protease inhibitors. These were developed to replace the use of aprotinin during and after cardiac surgery, including surgeries with cardiopulmonary bypass which cause blood loss and hemorrhagic complications. CU-2010 and CU-2020 were developed to avoid many issues associated with the use of aprotinin, including the risk of an allergic reaction and infection. Since the isolation of aprotinin is expensive, a drug with a simpler synthesis was desired.".
- CU-2010_and_CU-2020 wikiPageID "38864487".
- CU-2010_and_CU-2020 wikiPageLength "4924".
- CU-2010_and_CU-2020 wikiPageOutDegree "12".
- CU-2010_and_CU-2020 wikiPageRevisionID "697621643".
- CU-2010_and_CU-2020 wikiPageWikiLink Aprotinin.
- CU-2010_and_CU-2020 wikiPageWikiLink Atomic_mass_unit.
- CU-2010_and_CU-2020 wikiPageWikiLink Cardiac_surgery.
- CU-2010_and_CU-2020 wikiPageWikiLink Cardiopulmonary_bypass.
- CU-2010_and_CU-2020 wikiPageWikiLink Category:Serine_protease_inhibitors.
- CU-2010_and_CU-2020 wikiPageWikiLink Half-life.
- CU-2010_and_CU-2020 wikiPageWikiLink Intravenous_therapy.
- CU-2010_and_CU-2020 wikiPageWikiLink PEGylation.
- CU-2010_and_CU-2020 wikiPageWikiLink Peptide.
- CU-2010_and_CU-2020 wikiPageWikiLink Plasmin.
- CU-2010_and_CU-2020 wikiPageWikiLink Polyethylene_glycol.
- CU-2010_and_CU-2020 wikiPageWikiLink Serpin.
- CU-2010_and_CU-2020 wikiPageUsesTemplate Template:Orphan.
- CU-2010_and_CU-2020 wikiPageUsesTemplate Template:Reflist.
- CU-2010_and_CU-2020 subject Category:Serine_protease_inhibitors.
- CU-2010_and_CU-2020 hypernym Compounds.
- CU-2010_and_CU-2020 type ChemicalCompound.
- CU-2010_and_CU-2020 comment "CU-2010 and CU-2020 are new synthetic compounds that act as serine protease inhibitors. These were developed to replace the use of aprotinin during and after cardiac surgery, including surgeries with cardiopulmonary bypass which cause blood loss and hemorrhagic complications. CU-2010 and CU-2020 were developed to avoid many issues associated with the use of aprotinin, including the risk of an allergic reaction and infection.".
- CU-2010_and_CU-2020 label "CU-2010 and CU-2020".
- CU-2010_and_CU-2020 wasDerivedFrom CU-2010_and_CU-2020?oldid=697621643.
- CU-2010_and_CU-2020 isPrimaryTopicOf CU-2010_and_CU-2020.